FIELD: medicine.
SUBSTANCE: invention is a method for selection of compounds for directed immune response modulation at a vaccination against plague, characterized by ex vivo performance on a blood cells suspension obtained prior to and one month after vaccination, incubated with the test substance at 37°C for 24 h with cytokine - IL-17, IFN-γ, TNF-α, IL-4 definition in production samples, and subsequent mathematical processing of the data obtained using the coefficients and indices, and if the value of the test substance T-cell immune system stimulation efficiency factor (IEF) exceeds the control 2 IEF in the range of 1.5 to 3.0 times, the test substance is considered suitable for directed immune response modulation.
EFFECT: implementation of the invention allows to increase the information content, accelerate and standardize selection of substances for directed immune response modulation after vaccination against plague.
3 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF USING COMPLEX OF WATER-SOLUBLE ANTIGENS OF PLAGUE MICROBE FOR EVALUATION OF ANTIPLAGUE IMMUNITY LEVEL | 2019 |
|
RU2725872C1 |
| METHOD OF PREDICTING DURATION OF PERIOD OF TICK-BORNE ENCEPHALITIS VIRUS ANTIGENEMIA | 2010 |
|
RU2439566C1 |
| ADJUVANT | 2020 |
|
RU2736933C1 |
| METHOD FOR OBTAINING VACCINE FOR TREATING TUBERCULOSIS AND OTHER INTRACELLULAR INFECTIOUS DISEASES AND VACCINE OBTAINED ACCORDING TO DECLARED METHOD | 2001 |
|
RU2262950C2 |
| METHOD FOR DETERMINING THE SPECIFIC CELLULAR IMMUNE RESPONSE TO CORONAVIRUS ANTIGENS (SARS-CoV-2) | 2021 |
|
RU2780369C1 |
| MEANS OF IMMUNOMODULATING ACTIVITY | 2017 |
|
RU2657819C1 |
| USE OF MONOMYCOLYL GLYCEROL (MMG) AS ADJUVANT | 2008 |
|
RU2479317C2 |
| VACCINE CONTAINING RIBOSOMAL PROTEIN EXTRACT (RPE) AND Th1-ACTIVATING ADJUVANT | 2009 |
|
RU2521499C2 |
| METHOD FOR ASSESSING IMMUNOGENICITY OF LIVE PLAGUE VACCINE USING IN VITRO ANTIGEN SPECIFIC CELLULAR TESTS | 2018 |
|
RU2680697C1 |
| BIOMARKERS FOR TUBERCULOSIS | 2014 |
|
RU2697549C2 |
